<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03151434</url>
  </required_header>
  <id_info>
    <org_study_id>1601583558</org_study_id>
    <nct_id>NCT03151434</nct_id>
  </id_info>
  <brief_title>Comparison of Three Different Pain Blocks for Subjects Undergoing VATS (Video Assisted Thoracoscopic Surgery) Procedure.</brief_title>
  <acronym>VATS</acronym>
  <official_title>Randomized Prospective Study Comparing Paravertebral Catheters, Single Shot Paravertebral Block, Thoracic Epidural, for Postoperative Analgesia Following Video-assisted Thoracoscopic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare three different pain control methods on subjects who&#xD;
      are scheduled to undergo VATS (video-assisted thoracoscopic surgery) procedures. The study&#xD;
      will compare their pain scores, narcotic needs, patient satisfaction scores, and narcotic&#xD;
      side effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients will be consented on the morning of surgery. All the thoracic epidurals and&#xD;
      ultrasound-guided paravertebral blocks will be placed preoperatively. The procedures will be&#xD;
      done using sterile technique with masks, hats, and sterile gloves. All procedures will be&#xD;
      placed under the supervision of the attending anesthesiologist on the acute pain service or&#xD;
      the attending anesthesiologist in the operating room.&#xD;
&#xD;
      Thoracic epidurals will be placed using the Arrow thoracic epidural kit. The epidural will be&#xD;
      placed at the appropriate level to cover the entry site for the VATS procedure. Placement&#xD;
      will be determined by anatomical landmarks. The epidural needle will be advanced toward the&#xD;
      epidural space utilizing a Paramedian approach and loss-of-resistance technique. A sterile&#xD;
      catheter will then be secured in place and the epidural infusion will be started at the end&#xD;
      of the case.&#xD;
&#xD;
      Ultrasound guided paravertebral catheter and single shot paravertebral block will be&#xD;
      accomplished using an ultrasound transducer at the thoracic level. This will be done using an&#xD;
      in-plane or out-of-plane approach, at the discretion of the anesthesia staff performing the&#xD;
      procedure. Then a needle will be inserted the needle into the paravertebral space and local&#xD;
      anesthetic injected. Then a catheter will be placed within the injectate and secured in place&#xD;
      in the case of the paravertebral catheter. The 0.2% Ropivicaine will be delivered by OnQ&#xD;
      pump.&#xD;
&#xD;
      General anesthesia will be induced and the patient will be placed in the lateral position for&#xD;
      the VATS procedure. The patients will be intubated with dual lumen endotracheal tubes and&#xD;
      placed on one-lung ventilation for the procedure.&#xD;
&#xD;
      All patients will receive intravenous patient-controlled analgesia (PCA hydromorphone)&#xD;
      post-operatively for breakthrough pain. They will also be scheduled on PO acetaminophen. PO&#xD;
      oxycodone PRN will be started on POD 1 once patients tolerate diet.&#xD;
&#xD;
      Opioid usage at 1,24,48,72 hours after the block will be recorded by a member of the research&#xD;
      team. Pain scores at rest and on movement (knee flexion) will be measured by the investigator&#xD;
      using Visual Analog Scale (VAS). Nausea will be measured using a categorical scoring system&#xD;
      (none=0; mild=1; moderate=2; severe=3). Sedation scores will also be assessed by a member of&#xD;
      the study team using a sedation scale (awake and alert=0; quietly awake=1; asleep but easily&#xD;
      roused=2; deep sleep=3). All these parameters will be measured at 1, 24, 48 and 72 hours&#xD;
      after the epidural or PVB. Patients will be encouraged to ambulate on postoperative day 1&#xD;
      under supervision.&#xD;
&#xD;
      All catheters will be removed by APS (Acute Pain Service) while patients are still in the&#xD;
      hospital. APS will continue to follow the patients until catheter removal. Patient's hospital&#xD;
      length of stay and readmission rate will be recorded from NSQIP (National Surgical Quality&#xD;
      Improvement Program) data.&#xD;
&#xD;
      All patients will receive a phone call 6 months after surgery for assessment for chronic&#xD;
      post-surgical pain. Patients will be assessed by a member of the research team over the&#xD;
      phone. They will be assessed on their pain score and narcotic usage by using the Brief Pain&#xD;
      Inventory. Study participation will conclude after the 6 month follow questionnaire has been&#xD;
      completed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 7, 2017</start_date>
  <completion_date type="Actual">July 30, 2018</completion_date>
  <primary_completion_date type="Actual">July 30, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients randomized to epidural, single shot paravertebral block, and paravertebral catheter</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Endpoint of This Study Will be VAS Pain Score at 24 Hours</measure>
    <time_frame>Pain scores will be measured 24 hours after surgery.</time_frame>
    <description>The VAS score will be taken with both rest and movement (knee flexion) and will be measured by a study team investigator using Visual Analog Scale (VAS). Using &quot;units on a scale&quot; of 1-10 for documentation with 10 being the worst pain and 0 being no pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Primary Endpoint of This Study Will be VAS Pain Score at 48 Hours</measure>
    <time_frame>Pain scores will be measured 48 hours after surgery.</time_frame>
    <description>The VAS scores will be taken with both rest and movement (knee flexion) and will be measured by a study team investigator using Visual Analog Scale (VAS). Using&quot;units on a scale&quot; scale of 1-10 for documentation with 10 being the worst pain and 0 being no pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint Includes Total Intravenous Opioid Consumption at 72 Hours</measure>
    <time_frame>Opioid consumption will be measured at 1 hour post op, 24,48, and 72 hours post op. The total amount will be recorded.</time_frame>
    <description>Opioid consumption will be collected by a study team member post operatively up to 3 days per protocol time requirements</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Average Nausea Scores Over 72 Hours</measure>
    <time_frame>Nausea scores will be documented at 1 hour post op, 24,48,and 72 hours after the surgery.The scores will then be averaged.</time_frame>
    <description>Nausea scores will be collected by a study team member post operatively up to 3 days per protocol. Nausea will be recorded as 0=none, 1=mild, 2=moderate, or 3=severe</description>
  </other_outcome>
  <other_outcome>
    <measure>Average Sedation Scores Over 72 Hours</measure>
    <time_frame>Sedation scores will be documented at 1 hour post op, 24,48,and 72 hours after the sugery. The scores will then be averaged.</time_frame>
    <description>Sedation scores will be documented by a study team member post operatively up to 3 days per protocol requirements. Determining if patient is 0=awake and alert, 1=quietly awake, 2=asleep and arousable, or 3=deep sleep.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subjects Overall Satisfaction Scores</measure>
    <time_frame>post operatively at hour 24</time_frame>
    <description>Subjects will be followed up at 24 hours post operatively by a study team member to document patient overall satisfaction scores. Score was recorded as 0=dissatisfied, 1=satisfied, 2=very satisfied.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subjects Overall Satisfaction Scores</measure>
    <time_frame>post operatively at hour 48</time_frame>
    <description>Subjects will be followed up at 48 hours post operatively by a study team member to document patient overall satisfaction scores. Scores will be recorded as 0=dissatisfied, 1=satisfied, 2=very satisfied.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">147</enrollment>
  <condition>Video Assisted Thoracoscopic Surgery</condition>
  <condition>Pain, Postoperative</condition>
  <condition>Pain, Acute</condition>
  <arm_group>
    <arm_group_label>Group #1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>US Guided Single Shot Paravertebral Block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group #2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>US Guided Paravertebral Catheter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group #3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Thoracic Epidural</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>US Guided Single Shot Paravertebral Block (0.2% ropivicaine infusion)</intervention_name>
    <description>Single shot paravertebral block will be placed under ultrasound guidance at the thoracic region prior to surgery.</description>
    <arm_group_label>Group #1</arm_group_label>
    <other_name>US Guided Single Shot Paravertebral Block</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>US Guided Paravertebral Catheter (0.2% ropivicaine bolus)</intervention_name>
    <description>Paravertebral catheter will be placed under ultrasound guidance at the thoracic region prior to surgery.</description>
    <arm_group_label>Group #2</arm_group_label>
    <other_name>US Guided Paravertebral Catheter</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thoracic Epidural (0.125% bupivicaine/hydromorphone)</intervention_name>
    <description>Epidural catheter will be placed in the thoracic region prior to surgery.</description>
    <arm_group_label>Group #3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pt undergoing VATS procedure at Indiana University Hospital&#xD;
&#xD;
          -  ASA 1,2,3 or 4&#xD;
&#xD;
          -  Age 18 or older, male or female&#xD;
&#xD;
          -  Desires Regional anesthesia for postoperative pain control&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any contraindication for Thoracic Epidural or Paravertebral block&#xD;
&#xD;
          -  History of substance abuse in the past 6 months&#xD;
&#xD;
          -  Patient staying intubated after surgery&#xD;
&#xD;
          -  Known allergy or other contraindications to the study medications , which include&#xD;
             dilaudid, bupivacaine, ropivacaine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yar Yeap, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bottiger BA, Esper SA, Stafford-Smith M. Pain management strategies for thoracotomy and thoracic pain syndromes. Semin Cardiothorac Vasc Anesth. 2014 Mar;18(1):45-56. doi: 10.1177/1089253213514484. Epub 2013 Dec 12. Review.</citation>
    <PMID>24336691</PMID>
  </reference>
  <reference>
    <citation>Daly DJ, Myles PS. Update on the role of paravertebral blocks for thoracic surgery: are they worth it? Curr Opin Anaesthesiol. 2009 Feb;22(1):38-43. doi: 10.1097/ACO.0b013e32831a4074. Review.</citation>
    <PMID>19237975</PMID>
  </reference>
  <reference>
    <citation>Dango S, Harris S, Offner K, Hennings E, Priebe HJ, Buerkle H, Passlick B, Loop T. Combined paravertebral and intrathecal vs thoracic epidural analgesia for post-thoracotomy pain relief. Br J Anaesth. 2013 Mar;110(3):443-9. doi: 10.1093/bja/aes394. Epub 2012 Nov 14.</citation>
    <PMID>23151421</PMID>
  </reference>
  <reference>
    <citation>Davies RG, Myles PS, Graham JM. A comparison of the analgesic efficacy and side-effects of paravertebral vs epidural blockade for thoracotomy--a systematic review and meta-analysis of randomized trials. Br J Anaesth. 2006 Apr;96(4):418-26. Epub 2006 Feb 13. Review. Erratum in: Br J Anaesth. 2007 Nov;99(5):768.</citation>
    <PMID>16476698</PMID>
  </reference>
  <reference>
    <citation>El-Morsy, W. Z. (2013). Thoracic epidural analgesia versus parenteral morphine for post-thoracotomy pain relief. Ain-Shams Journal of Anaesthesiology, 6(2), 180.</citation>
  </reference>
  <reference>
    <citation>Fortier S, Hanna HA, Bernard A, Girard C. Comparison between systemic analgesia, continuous wound catheter analgesia and continuous thoracic paravertebral block: a randomised, controlled trial of postthoracotomy pain management. Eur J Anaesthesiol. 2012 Nov;29(11):524-30. doi: 10.1097/EJA.0b013e328357e5a1.</citation>
    <PMID>22914044</PMID>
  </reference>
  <reference>
    <citation>Fibla JJ, Molins L, Mier JM, Sierra A, Carranza D, Vidal G. The efficacy of paravertebral block using a catheter technique for postoperative analgesia in thoracoscopic surgery: a randomized trial. Eur J Cardiothorac Surg. 2011 Oct;40(4):907-11. doi: 10.1016/j.ejcts.2010.12.043. Epub 2011 Feb 11.</citation>
    <PMID>21316259</PMID>
  </reference>
  <reference>
    <citation>Helms O, Mariano J, Hentz JG, Santelmo N, Falcoz PE, Massard G, Steib A. Intra-operative paravertebral block for postoperative analgesia in thoracotomy patients: a randomized, double-blind, placebo-controlled study. Eur J Cardiothorac Surg. 2011 Oct;40(4):902-6. doi: 10.1016/j.ejcts.2011.01.067. Epub 2011 Mar 5. Review.</citation>
    <PMID>21377888</PMID>
  </reference>
  <reference>
    <citation>Kaya FN, Turker G, Mogol EB, Bayraktar S. Thoracic paravertebral block for video-assisted thoracoscopic surgery: single injection versus multiple injections. J Cardiothorac Vasc Anesth. 2012 Feb;26(1):90-4. doi: 10.1053/j.jvca.2011.09.008. Epub 2011 Nov 4.</citation>
    <PMID>22055006</PMID>
  </reference>
  <reference>
    <citation>Komatsu T, Sowa T, Takahashi K, Fujinaga T. Paravertebral block as a promising analgesic modality for managing post-thoracotomy pain. Ann Thorac Cardiovasc Surg. 2014;20(2):113-6. Epub 2013 Feb 28.</citation>
    <PMID>23445804</PMID>
  </reference>
  <reference>
    <citation>Mackay, J. H., &amp; Gray, S. J. (2013). Principles and Practice of Anesthesia for Thoracic Surgery. British Journal of Anaesthesia, 110(5), 857-858.</citation>
  </reference>
  <reference>
    <citation>Richardson J, Sabanathan S, Jones J, Shah RD, Cheema S, Mearns AJ. A prospective, randomized comparison of preoperative and continuous balanced epidural or paravertebral bupivacaine on post-thoracotomy pain, pulmonary function and stress responses. Br J Anaesth. 1999 Sep;83(3):387-92.</citation>
    <PMID>10655907</PMID>
  </reference>
  <reference>
    <citation>Shelley B, Macfie A. Where now for thoracic paravertebral blockade? Anaesthesia. 2012 Dec;67(12):1317-20. doi: 10.1111/j.1365-2044.2012.07310.x.</citation>
    <PMID>23130723</PMID>
  </reference>
  <reference>
    <citation>Slater, B., &amp; Frost, E. A. (2012). Pain Management After Thoracic Surgery.Topics in Pain Management, 28(3), 1-8.</citation>
  </reference>
  <reference>
    <citation>Yoshida T, Fujiwara T, Furutani K, Ohashi N, Baba H. Effects of ropivacaine concentration on the spread of sensory block produced by continuous thoracic paravertebral block: a prospective, randomised, controlled, double-blind study. Anaesthesia. 2014 Mar;69(3):231-9. doi: 10.1111/anae.12531. Epub 2014 Jan 21.</citation>
    <PMID>24447266</PMID>
  </reference>
  <reference>
    <citation>Yoshioka M, Mori T, Kobayashi H, Iwatani K, Yoshimoto K, Terasaki H, Nomori H. The efficacy of epidural analgesia after video-assisted thoracoscopic surgery: a randomized control study. Ann Thorac Cardiovasc Surg. 2006 Oct;12(5):313-8.</citation>
    <PMID>17095972</PMID>
  </reference>
  <results_reference>
    <citation>Yeap YL, Wolfe JW, Backfish-White KM, Young JV, Stewart J, Ceppa DP, Moser EAS, Birdas TJ. Randomized Prospective Study Evaluating Single-Injection Paravertebral Block, Paravertebral Catheter, and Thoracic Epidural Catheter for Postoperative Regional Analgesia After Video-Assisted Thoracoscopic Surgery. J Cardiothorac Vasc Anesth. 2020 Jul;34(7):1870-1876. doi: 10.1053/j.jvca.2020.01.036. Epub 2020 Jan 25.</citation>
    <PMID>32144059</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 22, 2017</study_first_submitted>
  <study_first_submitted_qc>May 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2017</study_first_posted>
  <results_first_submitted>September 18, 2020</results_first_submitted>
  <results_first_submitted_qc>January 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 27, 2021</results_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Yar Yeap</investigator_full_name>
    <investigator_title>Director, Acute Pain Service Assistant Professor of Clinical Anesthesiology Indiana University School of Medicine Department of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>VATS</keyword>
  <keyword>pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydromorphone</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 15, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT03151434/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group #1</title>
          <description>US Guided Single Shot Paravertebral Block&#xD;
US Guided Single Shot Paravertebral Block (0.2% ropivicaine infusion): Single shot paravertebral block will be placed under ultrasound guidance at the thoracic region prior to surgery.</description>
        </group>
        <group group_id="P2">
          <title>Group #2</title>
          <description>US Guided Paravertebral Catheter&#xD;
US Guided Paravertebral Catheter (0.2% ropivicaine bolus): Paravertebral catheter will be placed under ultrasound guidance at the thoracic region prior to surgery.</description>
        </group>
        <group group_id="P3">
          <title>Group #3</title>
          <description>Thoracic Epidural&#xD;
Thoracic Epidural (0.125% bupivicaine/hydromorphone): Epidural catheter will be placed in the thoracic region prior to surgery.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>US Guided Single Shot Paravertebral Block</title>
          <description>group 1- US Guided Single Shot Paravertebral Block&#xD;
US Guided Single Shot Paravertebral Block (0.2% ropivicaine infusion): Single shot paravertebral block will be placed under ultrasound guidance at the thoracic region prior to surgery.</description>
        </group>
        <group group_id="B2">
          <title>US Guided Paravertebral Catheter</title>
          <description>group 2- US Guided Paravertebral Catheter&#xD;
US Guided Paravertebral Catheter (0.2% ropivicaine bolus): Paravertebral catheter will be placed under ultrasound guidance at the thoracic region prior to surgery.</description>
        </group>
        <group group_id="B3">
          <title>Thoracic Epidural</title>
          <description>group 3- Thoracic Epidural&#xD;
Thoracic Epidural (0.125% bupivicaine/hydromorphone): Epidural catheter will be placed in the thoracic region prior to surgery.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="40"/>
            <count group_id="B4" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.5" lower_limit="48.5" upper_limit="70"/>
                    <measurement group_id="B2" value="62" lower_limit="45.5" upper_limit="69.5"/>
                    <measurement group_id="B3" value="61" lower_limit="52" upper_limit="70"/>
                    <measurement group_id="B4" value="62" lower_limit="48" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="104"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>height</title>
          <units>Centimeter</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171" lower_limit="162" upper_limit="177.8"/>
                    <measurement group_id="B2" value="167.6" lower_limit="165" upper_limit="173.9"/>
                    <measurement group_id="B3" value="173.5" lower_limit="161.3" upper_limit="179.3"/>
                    <measurement group_id="B4" value="170" lower_limit="162" upper_limit="177.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>weight</title>
          <units>Kilogram</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88.4" lower_limit="72.2" upper_limit="105"/>
                    <measurement group_id="B2" value="77.7" lower_limit="67" upper_limit="90.4"/>
                    <measurement group_id="B3" value="87.3" lower_limit="65.8" upper_limit="106.7"/>
                    <measurement group_id="B4" value="84.1" lower_limit="67.1" upper_limit="102.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Endpoint of This Study Will be VAS Pain Score at 24 Hours</title>
        <description>The VAS score will be taken with both rest and movement (knee flexion) and will be measured by a study team investigator using Visual Analog Scale (VAS). Using &quot;units on a scale&quot; of 1-10 for documentation with 10 being the worst pain and 0 being no pain</description>
        <time_frame>Pain scores will be measured 24 hours after surgery.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>US Guided Single Shot Paravertebral Block</title>
            <description>group 1- US Guided Single Shot Paravertebral Block&#xD;
US Guided Single Shot Paravertebral Block (0.2% ropivicaine infusion): Single shot paravertebral block will be placed under ultrasound guidance at the thoracic region prior to surgery.</description>
          </group>
          <group group_id="O2">
            <title>US Guided Paravertebral Catheter</title>
            <description>group 2- US Guided Paravertebral Catheter&#xD;
US Guided Paravertebral Catheter (0.2% ropivicaine bolus): Paravertebral catheter will be placed under ultrasound guidance at the thoracic region prior to surgery.</description>
          </group>
          <group group_id="O3">
            <title>Thoracic Epidural</title>
            <description>group 3- Thoracic Epidural&#xD;
Thoracic Epidural (0.125% bupivicaine/hydromorphone): Epidural catheter will be placed in the thoracic region prior to surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Endpoint of This Study Will be VAS Pain Score at 24 Hours</title>
          <description>The VAS score will be taken with both rest and movement (knee flexion) and will be measured by a study team investigator using Visual Analog Scale (VAS). Using &quot;units on a scale&quot; of 1-10 for documentation with 10 being the worst pain and 0 being no pain</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="3.0" upper_limit="5.5"/>
                    <measurement group_id="O2" value="4.5" lower_limit="2.5" upper_limit="6.0"/>
                    <measurement group_id="O3" value="3.0" lower_limit="1.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Primary Endpoint of This Study Will be VAS Pain Score at 48 Hours</title>
        <description>The VAS scores will be taken with both rest and movement (knee flexion) and will be measured by a study team investigator using Visual Analog Scale (VAS). Using&quot;units on a scale&quot; scale of 1-10 for documentation with 10 being the worst pain and 0 being no pain</description>
        <time_frame>Pain scores will be measured 48 hours after surgery.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>US Guided Single Shot Paravertebral Block</title>
            <description>group 1- US Guided Single Shot Paravertebral Block&#xD;
US Guided Single Shot Paravertebral Block (0.2% ropivicaine infusion): Single shot paravertebral block will be placed under ultrasound guidance at the thoracic region prior to surgery.</description>
          </group>
          <group group_id="O2">
            <title>US Guided Paravertebral Catheter</title>
            <description>group 2- US Guided Paravertebral Catheter&#xD;
US Guided Paravertebral Catheter (0.2% ropivicaine bolus): Paravertebral catheter will be placed under ultrasound guidance at the thoracic region prior to surgery.</description>
          </group>
          <group group_id="O3">
            <title>Thoracic Epidural</title>
            <description>group 3- Thoracic Epidural&#xD;
Thoracic Epidural (0.125% bupivicaine/hydromorphone): Epidural catheter will be placed in the thoracic region prior to surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Endpoint of This Study Will be VAS Pain Score at 48 Hours</title>
          <description>The VAS scores will be taken with both rest and movement (knee flexion) and will be measured by a study team investigator using Visual Analog Scale (VAS). Using&quot;units on a scale&quot; scale of 1-10 for documentation with 10 being the worst pain and 0 being no pain</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="4.0" lower_limit="2.0" upper_limit="6.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Endpoint Includes Total Intravenous Opioid Consumption at 72 Hours</title>
        <description>Opioid consumption will be collected by a study team member post operatively up to 3 days per protocol time requirements</description>
        <time_frame>Opioid consumption will be measured at 1 hour post op, 24,48, and 72 hours post op. The total amount will be recorded.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group #1</title>
            <description>US Guided Single Shot Paravertebral Block&#xD;
US Guided Single Shot Paravertebral Block (0.2% ropivicaine infusion): Single shot paravertebral block will be placed under ultrasound guidance at the thoracic region prior to surgery.</description>
          </group>
          <group group_id="O2">
            <title>Group #2</title>
            <description>US Guided Paravertebral Catheter&#xD;
US Guided Paravertebral Catheter (0.2% ropivicaine bolus): Paravertebral catheter will be placed under ultrasound guidance at the thoracic region prior to surgery.</description>
          </group>
          <group group_id="O3">
            <title>Group #3</title>
            <description>Thoracic Epidural&#xD;
Thoracic Epidural (0.125% bupivicaine/hydromorphone): Epidural catheter will be placed in the thoracic region prior to surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Endpoint Includes Total Intravenous Opioid Consumption at 72 Hours</title>
          <description>Opioid consumption will be collected by a study team member post operatively up to 3 days per protocol time requirements</description>
          <units>miligram morphine equivalent</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57" lower_limit="18" upper_limit="96"/>
                    <measurement group_id="O2" value="35" lower_limit="15" upper_limit="89"/>
                    <measurement group_id="O3" value="21.3" lower_limit="7.5" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Average Nausea Scores Over 72 Hours</title>
        <description>Nausea scores will be collected by a study team member post operatively up to 3 days per protocol. Nausea will be recorded as 0=none, 1=mild, 2=moderate, or 3=severe</description>
        <time_frame>Nausea scores will be documented at 1 hour post op, 24,48,and 72 hours after the surgery.The scores will then be averaged.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group #1</title>
            <description>US Guided Single Shot Paravertebral Block&#xD;
US Guided Single Shot Paravertebral Block (0.2% ropivicaine infusion): Single shot paravertebral block will be placed under ultrasound guidance at the thoracic region prior to surgery.</description>
          </group>
          <group group_id="O2">
            <title>Group #2</title>
            <description>US Guided Paravertebral Catheter&#xD;
US Guided Paravertebral Catheter (0.2% ropivicaine bolus): Paravertebral catheter will be placed under ultrasound guidance at the thoracic region prior to surgery.</description>
          </group>
          <group group_id="O3">
            <title>Group #3</title>
            <description>Thoracic Epidural&#xD;
Thoracic Epidural (0.125% bupivicaine/hydromorphone): Epidural catheter will be placed in the thoracic region prior to surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Nausea Scores Over 72 Hours</title>
          <description>Nausea scores will be collected by a study team member post operatively up to 3 days per protocol. Nausea will be recorded as 0=none, 1=mild, 2=moderate, or 3=severe</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.27" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O3" value="0.29" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Average Sedation Scores Over 72 Hours</title>
        <description>Sedation scores will be documented by a study team member post operatively up to 3 days per protocol requirements. Determining if patient is 0=awake and alert, 1=quietly awake, 2=asleep and arousable, or 3=deep sleep.</description>
        <time_frame>Sedation scores will be documented at 1 hour post op, 24,48,and 72 hours after the sugery. The scores will then be averaged.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group #1</title>
            <description>US Guided Single Shot Paravertebral Block&#xD;
US Guided Single Shot Paravertebral Block (0.2% ropivicaine infusion): Single shot paravertebral block will be placed under ultrasound guidance at the thoracic region prior to surgery.</description>
          </group>
          <group group_id="O2">
            <title>Group #2</title>
            <description>US Guided Paravertebral Catheter&#xD;
US Guided Paravertebral Catheter (0.2% ropivicaine bolus): Paravertebral catheter will be placed under ultrasound guidance at the thoracic region prior to surgery.</description>
          </group>
          <group group_id="O3">
            <title>Group #3</title>
            <description>Thoracic Epidural&#xD;
Thoracic Epidural (0.125% bupivicaine/hydromorphone): Epidural catheter will be placed in the thoracic region prior to surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Sedation Scores Over 72 Hours</title>
          <description>Sedation scores will be documented by a study team member post operatively up to 3 days per protocol requirements. Determining if patient is 0=awake and alert, 1=quietly awake, 2=asleep and arousable, or 3=deep sleep.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.32" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O3" value="0.22" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subjects Overall Satisfaction Scores</title>
        <description>Subjects will be followed up at 24 hours post operatively by a study team member to document patient overall satisfaction scores. Score was recorded as 0=dissatisfied, 1=satisfied, 2=very satisfied.</description>
        <time_frame>post operatively at hour 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group #1</title>
            <description>US Guided Single Shot Paravertebral Block&#xD;
US Guided Single Shot Paravertebral Block (0.2% ropivicaine infusion): Single shot paravertebral block will be placed under ultrasound guidance at the thoracic region prior to surgery.</description>
          </group>
          <group group_id="O2">
            <title>Group #2</title>
            <description>US Guided Paravertebral Catheter&#xD;
US Guided Paravertebral Catheter (0.2% ropivicaine bolus): Paravertebral catheter will be placed under ultrasound guidance at the thoracic region prior to surgery.</description>
          </group>
          <group group_id="O3">
            <title>Group #3</title>
            <description>Thoracic Epidural&#xD;
Thoracic Epidural (0.125% bupivicaine/hydromorphone): Epidural catheter will be placed in the thoracic region prior to surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Overall Satisfaction Scores</title>
          <description>Subjects will be followed up at 24 hours post operatively by a study team member to document patient overall satisfaction scores. Score was recorded as 0=dissatisfied, 1=satisfied, 2=very satisfied.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0.95" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O3" value="1.33" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subjects Overall Satisfaction Scores</title>
        <description>Subjects will be followed up at 48 hours post operatively by a study team member to document patient overall satisfaction scores. Scores will be recorded as 0=dissatisfied, 1=satisfied, 2=very satisfied.</description>
        <time_frame>post operatively at hour 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group #1</title>
            <description>US Guided Single Shot Paravertebral Block&#xD;
US Guided Single Shot Paravertebral Block (0.2% ropivicaine infusion): Single shot paravertebral block will be placed under ultrasound guidance at the thoracic region prior to surgery.</description>
          </group>
          <group group_id="O2">
            <title>Group #2</title>
            <description>US Guided Paravertebral Catheter&#xD;
US Guided Paravertebral Catheter (0.2% ropivicaine bolus): Paravertebral catheter will be placed under ultrasound guidance at the thoracic region prior to surgery.</description>
          </group>
          <group group_id="O3">
            <title>Group #3</title>
            <description>Thoracic Epidural&#xD;
Thoracic Epidural (0.125% bupivicaine/hydromorphone): Epidural catheter will be placed in the thoracic region prior to surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Overall Satisfaction Scores</title>
          <description>Subjects will be followed up at 48 hours post operatively by a study team member to document patient overall satisfaction scores. Scores will be recorded as 0=dissatisfied, 1=satisfied, 2=very satisfied.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="1.05" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O3" value="1.32" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants were followed for 6 months after surgery. Any adverse event from surgery day till 6 months after surgery are documented.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>US Guided Single Shot Paravertebral Block</title>
          <description>group 1- US Guided Single Shot Paravertebral Block&#xD;
US Guided Single Shot Paravertebral Block (0.2% ropivicaine infusion): Single shot paravertebral block will be placed under ultrasound guidance at the thoracic region prior to surgery.</description>
        </group>
        <group group_id="E2">
          <title>US Guided Paravertebral Catheter</title>
          <description>group 2- US Guided Paravertebral Catheter&#xD;
US Guided Paravertebral Catheter (0.2% ropivicaine bolus): Paravertebral catheter will be placed under ultrasound guidance at the thoracic region prior to surgery.</description>
        </group>
        <group group_id="E3">
          <title>Thoracic Epidural</title>
          <description>group 3- Thoracic Epidural&#xD;
Thoracic Epidural (0.125% bupivicaine/hydromorphone): Epidural catheter will be placed in the thoracic region prior to surgery.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Yar Luan Yeap</name_or_title>
      <organization>Indiana University Department of Anesthesiology</organization>
      <phone>3172740275</phone>
      <email>yyeap@iupui.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

